EcoDrugPlus

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSCSEG00000005031
Gene Symbol: P2RY4
4 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSCSEG00000018492
Gene Symbol: P2RY6
4 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSCSEG00000005898
Gene Symbol: RAMP1
3 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSCSEG00000019063
Gene Symbol: RAMP1
4 Cross references
190 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSCSEG00000009905
Gene Symbol: RIPK1
3 Cross references
198 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSCSEG00000007230
Gene Symbol: LOC103385096
3 Cross references
207 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSCSEG00000015159
Gene Symbol: RPTOR
1 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSCSEG00000021336
Gene Symbol: LOC103385502
3 Cross references
220 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSCSEG00000010826
Gene Symbol: RET
3 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSCSEG00000013437
Gene Symbol: RARA
4 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSCSEG00000010288
Gene Symbol: RARB
4 Cross references
394 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSCSEG00000004206
Gene Symbol: LOC103388357
2 Cross references
380 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).